Cue Biopharma (NASDAQ:CUE) Trading Up 2.9% - What's Next?

Key Points

• Cue Biopharma's shares increased by 2.9%, closing at $0.71 with a trading volume of 108,109 shares, down 14% from its average daily volume.
• The company reported quarterly earnings, with an EPS of ($0.09), surpassing the estimate of ($0.13), indicating better-than-expected financial performance.
• Institutional investors hold 35.04% of Cue Biopharma's stock, with notable increases in positions from firms like Northwestern Mutual and Jane Street Group.

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) shares rose 2.9% during trading on Friday . The stock traded as high as $0.71 and last traded at $0.71. Approximately 108,109 shares changed hands during trading, a decline of 14% from the average daily volume of 125,219 shares. The stock had previously closed at $0.69.

Cue Biopharma Price Performance

The stock has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $0.77. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The stock has a market cap of $54.55 million, a price-to-earnings ratio of -1.27 and a beta of 1.58.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.04. The company had revenue of $2.95 million for the quarter, compared to analyst estimates of $2.00 million. Cue Biopharma had a negative return on equity of 230.13% and a negative net margin of 469.35%. As a group, equities research analysts forecast that Cue Biopharma, Inc. will post -0.76 EPS for the current year.

Institutional Investors Weigh In On Cue Biopharma

Several large investors have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. increased its position in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock worth $57,000 after acquiring an additional 73,000 shares during the period. Jane Street Group LLC boosted its holdings in Cue Biopharma by 145.9% in the fourth quarter. Jane Street Group LLC now owns 63,767 shares of the company's stock valued at $70,000 after acquiring an additional 37,832 shares in the last quarter. Angeles Wealth Management LLC purchased a new position in Cue Biopharma in the 2nd quarter worth about $82,000. Chicago Partners Investment Group LLC bought a new position in Cue Biopharma in the 1st quarter worth approximately $82,000. Finally, Northern Trust Corp grew its position in shares of Cue Biopharma by 50.5% during the 4th quarter. Northern Trust Corp now owns 208,206 shares of the company's stock worth $227,000 after buying an additional 69,892 shares in the last quarter. Institutional investors own 35.04% of the company's stock.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.